Phase I study of DCs therapy encoding mRNA derived from cancer antigens targeting advanced HCC & pancreatic cancer.

Phase I study of DCs therapy encoding mRNA derived from cancer antigens targeting advanced HCC & pancreatic cancer. - Phase I study of DCs therapy encoding mRNA derived from cancer antigens targeting advanced HCC & pancreatic cancer.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005836

Enrollment

Registered

2011-06-26

Start date

2004-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HCC , Pancreatic cancer

Interventions

dose escalation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Evaluable tumor lesion(s) 2. Predicted life expectancy of at least 3 months 3. Performance status 0-1 (ECOG) 4. No radiotherapy, chemotherapy or immunotherapy within 4 weeks prior to the study 5. Written informed consent

Exclusion criteria

Exclusion criteria: 1. Adequate baseline organ functions 2. No history of serious allergic

Design outcomes

Primary

Measure	Time frame
To evaluate the safety and to find out the recommended dose	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

Phase I study of DCs therapy encoding mRNA derived from cancer antigens targeting advanced HCC &amp; pancreatic cancer.